☰

Megan E. McNerney, Ph.D. - Publications

Affiliations: 
2005 University of Chicago, Chicago, IL 
Area:
Immunology
Tree Info Grants Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Imgruet MK, An N, Khan S, Lutze JK, Hu B, Kron SJ, Gurbuxani S, McNerney ME. Deficiency of CUX1, Encoded on 7q, Blocks the Normal HSC DNA Damage Response and Drives Highly Penetrant Therapy-Related Myeloid Neoplasms in Mice Blood. 134: 641-641. DOI: 10.1182/Blood-2019-130717  0.35
2018 McNerney ME, Le Beau MM. The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells. Cell Stem Cell. 23: 634-635. PMID 30388419 DOI: 10.1016/J.Stem.2018.10.003  0.307
2018 An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. PMID 29592892 DOI: 10.1182/Blood-2017-10-810028  0.368
2017 Arthur RK, An N, Khan S, McNerney ME. The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters. Nucleic Acids Research. PMID 28369554 DOI: 10.1093/Nar/Gkx218  0.31
2016 Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM. Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. PMID 26944478 DOI: 10.3324/Haematol.2015.139527  0.304
2016 Arthur RK, An N, Kahn S, McNerney ME. Enhancer-Promoter Looping Deciphers Dosage of the Haploinsufficient Transcription Factor, CUX1 Blood. 128: 2700-2700. DOI: 10.1182/Blood.V128.22.2700.2700  0.303
2015 Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics. 47: 539-43. PMID 25822087 DOI: 10.1038/Ng.3251  0.302
2015 Voce DJ, Schmitt AM, Uppal A, McNerney ME, Bernal GM, Cahill KE, Wahlstrom JS, Nassiri A, Yu X, Crawley CD, White KP, Onel K, Weichselbaum RR, Yamini B. Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor. Oncogene. 34: 2807-13. PMID 25043302 DOI: 10.1038/Onc.2014.211  0.339
2013 Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discovery. 3: 993-1001. PMID 23733505 DOI: 10.1158/2159-8290.Cd-13-0096  0.332
2013 McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, Yu S, Ko J, Sandall BP, Stricker T, Anastasi J, Grossman RL, Cunningham JM, Le Beau MM, White KP. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 121: 975-83. PMID 23212519 DOI: 10.1182/Blood-2012-04-426965  0.354
2013 Stoddart A, Fernald A, Bergerson RJ, Wang J, McNerney ME, Karrison T, Anastasi J, Bartom E, Sarver AG, Qian Z, Wolff L, Largaespada DA, Beau MMl. Retroviral Insertional Mutagenesis In Egr1+/- mice, Haploinsufficient For a Human Del(5q) Myeloid Leukemia Gene, Develop Myeloid Neoplasms With Proviral Insertions In Genes Syntenic To Human 5q Blood. 122: 1275-1275. DOI: 10.1182/Blood.V122.21.1275.1275  0.363
2012 McNerney ME, Brown CD, Wang X, Karmakar S, Bandlamudi C, Yu S, Anastasi J, Beau MML, White K. Abstract LB-411: RNA sequencing reveals CUX1 to be a conserved tumor suppressor in acute myeloid leukemia associated with loss or deletion of chromosome 7 Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-411  0.34
2011 Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM. Genetic pathways leading to therapy-related myeloid neoplasms. Mediterranean Journal of Hematology and Infectious Diseases. 3: e2011019. PMID 21713073 DOI: 10.4084/Mjhid.2011.019  0.316
2010 McNerney ME, Brown CD, White KP. Next-Generation Sequencing Analysis of 23 Therapy-Related Acute Myeloid Leukemia Transcriptomes Blood. 116: 850-850. DOI: 10.1182/Blood.V116.21.850.850  0.332
2007 Alegre ML, McNerney ME. Natural killer cell subsets in allograft rejection and tolerance. Current Opinion in Organ Transplantation. 12: 10-16. PMID 27792083 DOI: 10.1097/Mot.0B013E3280129F2A  0.339
2006 McNerney ME, Lee KM, Zhou P, Molinero L, Mashayekhi M, Guzior D, Sattar H, Kuppireddi S, Wang CR, Kumar V, Alegre ML. Role of natural killer cell subsets in cardiac allograft rejection. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 6: 505-13. PMID 16468959 DOI: 10.1111/J.1600-6143.2005.01226.X  0.558
2006 McNerney ME, Kumar V. The CD2 family of natural killer cell receptors. Current Topics in Microbiology and Immunology. 298: 91-120. PMID 16323413 DOI: 10.1007/3-540-27743-9_5  0.534
2006 Lee KM, Forman JP, McNerney ME, Stepp S, Kuppireddi S, Guzior D, Latchman YE, Sayegh MH, Yagita H, Park CK, Oh SB, Wülfing C, Schatzle J, Mathew PA, Sharpe AH, et al. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood. 107: 3181-8. PMID 15905190 DOI: 10.1182/Blood-2005-01-0185  0.557
2005 McNerney ME, Guzior D, Kumar V. 2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood. 106: 1337-40. PMID 15870174 DOI: 10.1182/Blood-2005-01-0357  0.559
2005 Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nature Reviews. Immunology. 5: 363-74. PMID 15841099 DOI: 10.1038/Nri1603  0.495
2005 Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 800-7. PMID 15634901 DOI: 10.4049/Jimmunol.174.2.800  0.551
2005 McNerney ME, Lee KM, Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Molecular Immunology. 42: 489-94. PMID 15607804 DOI: 10.1016/J.Molimm.2004.07.032  0.566
2004 Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M, Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. The Journal of Experimental Medicine. 199: 1245-54. PMID 15123744 DOI: 10.1084/Jem.20031989  0.564
2001 Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 6627-34. PMID 11086108 DOI: 10.4049/Jimmunol.165.11.6627  0.408
Show low-probability matches.